The Applicability of Polygenic Risk Scores in Under-Represented Populations

AHRQ. 2022. National Healthcare Quality and Disparities Report. Agency for Healthcare Research and Quality: Rockville, MD, USA; 2022.

American Society of Human Genetics. Diversity, Equity, and Inclusion. 2022. Available from: https://www.ashg.org/membership/diversity-inclusion/ [Last accessed: June 14, 2023].

Colby SL , Ortman JM . Projections of the Size and Composition of the U.S. Population: 2014 to 2060. Current Population Reports. U.S. Census Bureau: Washington, DC, USA; 2015.

Conti DV , Darst BF , Moss LC , et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet, 2021; 53(1):65-75; doi: 10.1038/s41588-020-00748-0

Ganguly P . NIH awards $38 million to improve utility of polygenic risk scores in diverse populations. National Human Genome Research Institute. 2021. Available from: https://www.genome.gov/news/news-release/nih-awards-38-million-dollars-to-improve-utility-of-polygenic-risk-scores-in-diverse-populations [Last accessed: June 8, 2023].

Khera AV , Chaffin M , Aragam KG , et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet, 2018; 50(9):1219-1224; doi: 10.1038/s41588-018-0183-z

Lewis CM , Vassos E . Polygenic risk scores: From research tools to clinical instruments. Genome Med, 2020; 12(1):44; doi: 10.1186/s13073-020-00742-5

Loos RJF. 15years of genome-wide association studies and no signs of slowing down. Nat Commun, 2020; 11(1):5900; doi: 10.1038/s41467-020-19653-5

Martin AR , Kanai M , Kamatani Y , et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet, 2019; 51(4):584-591; doi: 10.1038/s41588-019-0379-x

McGuinness M , Fassi E , Wang C , et al. Breast cancer polygenic risk scores in the clinical cancer genetic counseling setting: Current practices and impact on patient management. J Genet Couns, 2021; 30(2):588-597; doi: 10.1002/jgc4.1347

Mills MC , Rahal C . The GWAS Diversity Monitor Tracks diversity by disease in real time. Nat Genet, 2020; 52(3):242-243; doi: 10.1038/s41588-020-0580-y

Morales J , Welter D , Bowler EH , et al. A standardized framework for representation of ancestry data in genomics studies, with application to the NHGRI-EBI GWAS Catalog. Genome Biol, 2018; 19(1):21; doi: 10.1186/s13059-018-1396-2

Multhaup ML , Kita R , Krock B , et al. The Science behind 23andMe's Type 2 Diabetes Report. White Paper 23-19. 23andMe; 2019.

Myriad Genetics. Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries. 2021. Available from: https://myriad.com/wp-content/blogs.dir/16/files/2021/09/Launch-of-RiskScore-for-all-ancestries.pdf [Last accessed: June 7, 2023].

National Institutes of Health. Diversity Statement. Bethesda, MD; 2016. Available from: https://diversity.nih.gov/about-us/diversity-statement [Last accessed: June 14, 2023].

O'Sullivan JW , Raghavan S , Marquez-Luna C , et al. Polygenic risk scores for cardiovascular disease: A scientific statement from the American Heart Association. Circulation, 2022; 146(8):e93-e118; doi: 10.1161/CIR.0000000000001077

U.S. Census Bureau. 2020: DEC Redistricting Data (Public Law 94-171); 2020.